sellWeak10b5-1 plan
Bradley L Campbell sold $323k of FOLD
President and CEO at AMICUS THERAPEUTICS, INC.. 22,500 shares at an average of $14.35, traded Mar 2, 2026, filed Mar 4, 2026.
Warning score
19Value
$323k
22,500 shares
Holdings after
998,680
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +14Trade size$323k at market
- 0Share of holdings soldSold 2.2% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-26-092114, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -22,500 | $14.35 | $323k | 998,680 | Mar 4, 2026 |
Related signals
Other insiders at AMICUS THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | AMICUS THERAPEUTICS, INC. | Bradley L Campbell President and CEO | $1.1M 75,000 shares | -7% | |
| 18Weak | AMICUS THERAPEUTICS, INC. | David Michael Clark Chief People Officer | $363k 25,642 shares | -9% | |
| 17Weak | AMICUS THERAPEUTICS, INC. | David Michael Clark Chief People Officer | $282k 25,643 shares | -9% | |
| 21Weak | AMICUS THERAPEUTICS, INC. | Bradley L Campbell President and CEO | $846k 77,926 shares | -6% | |
| 16Weak | AMICUS THERAPEUTICS, INC. | Bradley L Campbell President and CEO | $146k 14,587 shares | -1% | |
| 24Weak | AMICUS THERAPEUTICS, INC. | Ellen Rosenberg Chief Legal Officer | $958k 95,621 shares | -18% | |
| 16Weak | AMICUS THERAPEUTICS, INC. | Bradley L Campbell President and CEO | $147k 14,587 shares | -1% | |
| 23Weak | AMICUS THERAPEUTICS, INC. | David Michael Clark Chief People Officer | $259k 25,643 shares | -8% | |
| 22Weak | AMICUS THERAPEUTICS, INC. | Jeff Castelli Chief Development Officer | $774k 76,158 shares | -15% | |
| 8Weak | AMICUS THERAPEUTICS, INC. | David Michael Clark Chief People Officer | $244k 25,643 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.